

## DAFTAR PUSTAKA

1. Qian G, Yang N, Ma AHY, Wang L, Li G, Chen X, et al. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China. *Clin Infect Dis*. 2020;71(15):861–2.
2. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. *Sci Total Environ*. 2020;730:1–19.
3. Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin J Il. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. *Int J Infect Dis*. 2020;98:180–6.
4. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. *JAMA Intern Med* |. 2020;180(8):1081–9.
5. Oster Y, Michael-Gayego A, Rivkin M, Levinson L, Wolf DG, Nir-Paz R. Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures? *Clin Microbiol Infect*. 2021;27:811–2.
6. WHO (2021). COVID-19 Weekly Epidemiological Update. World Health Organization. <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-may-2021>- Diakses Maret 2021
7. WHO (2021). Coronavirus disease 2019 (COVID-19). *Situat Report*, 32. World Health Organization. [https://cdn.who.int/media/docs/defaultsource/searo/indonesia/covid19/external-situation-report-55\\_12-may-2021.pdf?sfvrsn=a453dd6c\\_5](https://cdn.who.int/media/docs/defaultsource/searo/indonesia/covid19/external-situation-report-55_12-may-2021.pdf?sfvrsn=a453dd6c_5) - Diakses Maret 2021
8. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? *Acta Trop*. 2021;214:1–13.
9. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and

- potential therapeutic opportunities. *Clin Chim Acta*. 2020;508:254–66.
10. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. 2020;382(16):1564–7.
  11. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. *Ann Intern Med*. 2021;174(1):69–79.
  12. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability, immunity and intervention. *Ageing Res Rev*. 2021;65:1–11.
  13. Chen Q, Wang L, Yu W, Xi H, Zhang Q, Chen X, et al. Recommendations for the prevention and treatment of the novel coronavirus pneumonia in the elderly in China. *AGING Med*. 2020;3(2):66–73.
  14. Fox-Lewis A, Fox-Lewis S, Beaumont J, Drinković D, Harrower J, Howe K, et al. SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study. *Pathology*. 2021;53(4):530–5.
  15. Kementerian Kesehatan Republik Indonesia. Pedoman pencegahan dan pengendalian corona virus disease (COVID-19) revisi ke-5. Jakarta: Kemenkes RI; 2020
  16. Gupta N, John A, Kokkottil MS, Varma M, Umakanth S, Saravu K. Clinical profile and outcomes of asymptomatic vs. symptomatic travellers diagnosed with COVID-19: An observational study from a coastal town in South India. *Drug Discov Ther*. 2021;15(1):1–8.
  17. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *J Infect*. 2020;80(4):401–6.
  18. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. *J Microbiol Immunol Infect*. 2021;54(1):12–6.
  19. Gao M, Yang L, Chen X, Deng Y, Yang S, Xu H, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. *Respir Med*. 2020;169:1–5.

20. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.* 2020;63(5):706–11.
21. AlJishi JM, Alhajjaj AH, Alkhabbaz FL, AlAbduljabar TH, Alsaif A, Alsaif H, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. *J Infect Public Health.* 2021;14(1):6–11.
22. Bhattacharya B, Kumar R, Meena VP, Soneja M, Singh A, Das R, et al. SARS-CoV-2 RT-PCR profile in 298 Indian COVID-19 patients: a retrospective observational study. *Pathog Dis.* 2021;79(1):2782–9.
23. Fleitas PE, Paz JA, Simoy MI, Vargas C, Cimino RO, Krolewiecki AJ, et al. Clinical diagnosis of COVID-19. A multivariate logistic regression analysis of symptoms of COVID-19 at presentation. *Germes.* 2021;11(2):221–37.
24. Gupta N, Ish P, Kumar R, Dev N, Yadav SR, Malhotra N, et al. Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India. *Monaldi Arch Chest Dis.* 2020;90(4):675–82.
25. Yoshimura Y, Sasaki H, Horiuchi H, Miyata N, Tachikawa N. Clinical characteristics of the coronavirus disease 2019 (COVID-19) outbreak on a cruise ship. *J Infect Chemother.* 2020;26(11):1177–80.
26. Li Y, Li K, Xiong W, Wang X, Liu C, Liu C, et al. Clinical characteristics and viral shedding kinetics of 38 asymptomatic patients with coronavirus disease 2019. *Medicine (Baltimore).* 2020;99(51):1–7.
27. Song R, Han B, Song M, Wang L, Conlon CP, Dong T, et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. *J Infect.* 2020;81(2):e26–30.
28. Ma Y, Xu Q, Wang F, Ma X, Wang X, Zhang X, et al. Characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, China. *Microbes Infect.* 2020;22(4–5):212–7.
29. Mei X, Zhang Y, Zhu H, Ling Y, Zou Y, Zhang Z, et al. Observations about symptomatic and asymptomatic infections of 494 patients with COVID-19 in Shanghai, China. *Am J Infect Control.* 2020;48(9):1045–50.

30. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect*. 2020;80(5):e1–6.
31. Chen Y, Chen X, Wang L, Zheng R. Clinical Characteristics of 33 Asymptomatic COVID-19 Infections in Wuhan, China. *J Infect Dev Ctries*. 2020;14(11):1252–5.
32. Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study. *Front Microbiol*. 2020;11:1–8.
33. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. *JAMA Netw Open*. 2020;3(5):1–4.
34. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. *JAMA Intern Med*. 2020;180(11):1447–52.
35. Pan Y, Yu X, Du X, Li Q, Li X, Qin T, et al. Epidemiological and Clinical Characteristics of 26 Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Carriers. *J Infect Dis*. 2020;221(12):1940–7.
36. Tan F, Wang K, Liu J, Liu D, Luo J, Zhou R. Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China. *Front Med*. 2020;7:1–5.
37. WHO(2021). Recommendations For National SARS-Cov-2 Testing Strategies And Diagnostic Capacities. World Health Organization.  
<https://www.who.int/publications/i/item/WHO-2019-nCoV-lab-testing-2021.1-eng> - Diakses Desember 2021
38. WHO(2021). Criteria for releasing COVID-19 patients from isolation. World Health Organization.  
<https://www.who.int/publications/i/item/criteria-for-releasing-covid-19-patients-from-isolation> - Diakses Januari 2022
39. Song W-L, Zou N, Guan W-H, Pan J-L, Xu W. Clinical characteristics of COVID-19 in family clusters: a systematic review. *World J Pediatr*.

- 2021;17(4):355–63.
40. Susanto AD, Rozaliyani A, Prasetyo B, Agustin H, Baskoro H, Arifin AR, et al. Epidemiological and Clinical Features of COVID-19 Patients at National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia. *Kesmas Natl Public Heal J.* 2021;16(1):11–6.
  41. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci.* 2020;12(1):1–5.
  42. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. *Circ Res.* 2020;126(10):1456–74.
  43. Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? *Clin Chem Lab Med.* 2020;58(9):1415–22.
  44. WHO(2021). Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (2019-nCoV) Infection is Suspected. World Health Organization.  
<https://apps.who.int/iris/handle/10665/330893> - Diakses Desember 2021
  45. Shu H, He S, Sun Y, Lin C, Lu Y, Liu J, et al. Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients. Quinn FD, editor. *Biomed Res Int.* 2021;2021:1–9.
  46. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov.* 2020;6(1):1–4.
  47. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med.* 2020;202(5):756–9.
  48. Grace C. Manifestasi Klinis dan Perjalanan Penyakit pada Pasien Penyakit Coronavirus-2019. *Majority.* 2020;9:49–55.
  49. McIntosh Kenneth. COVID-19: Clinical Features. UpToDate.  
<https://www.uptodate.com/contents/covid-19-clinical-features> - Diakses Desember 2021

50. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis*. 2020;20(6):656–7.
51. Kong JD, Tekwa EW, Gignoux-Wolfsohn SA. Social, economic, and environmental factors influencing the basic reproduction number of COVID-19 across countries. Avino P, editor. *PLoS One*. 2021;16(6):1–17.
52. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med*. 2020;26(8):1205–11.
53. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of sars-cov-2: A review of viral, host, and environmental factors. *Ann Intern Med*. 2021;174(1):69–79.
54. Bhat TA, Kalathil SG, Bogner PN, Blount BC, Goniewicz ML, Thanavala YM. An Animal Model of Inhaled Vitamin E Acetate and EVALI-like Lung Injury. *N Engl J Med*. 2020;382(12):1175–7.
55. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. *J Virol*. 2005;79(23):14614–21.
56. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability, immunity and intervention. *Ageing Res Rev*. 2021;65:1–13.
57. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? *Front Physiol*. 2021;11:1–23.
58. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Sex-Bias in COVID-19: A Meta-Analysis and Review of Sex Differences in Disease and Immunity. *SSRN Electron J*. 2020;11:1–26.
59. Bourgonje AR, Abdulle AE, Timens W, Hillebrands J, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19) Arno. *J Pathol*.

- 2020;251(3):228–48.
60. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. *Eur J Clin Microbiol Infect Dis*. 2021;40(5):905–19.
  61. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med*. 2020;8(4):e20.
  62. Rodrigues R, Costa de Oliveira S. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review. *Microorganisms*. 2021;9(8):1–14.
  63. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T-L, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. *Eur Respir J*. 2020;55(5):1–5.
  64. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626–38.
  65. Nikolai LA, Meyer CG, Kreamsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. *Int J Infect Dis*. 2020;100:112–6.
  66. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol*. 2017;198(10):4046–53.
  67. Yan D, Zhang X, Chen C, Jiang D, Liu X, Zhou Y, et al. Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis. *Front Public Heal*. 2021;9:1–11.
  68. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. *Lancet*. 2020;395(10233):1339–40.
  69. Hoffman EN, Kawachi H, Hirayama A, Zhang J, Murayama A, Masui J, et al. Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan. *Environ Health Prev Med*. 2021;26(1):1–11.
  70. Hao S, Lian J, Lu Y, Jia H, Hu J, Yu G, et al. Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the

Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study. *J Infect Dis.* 2020;222(3):367–71.

71. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ.* 2020;369:1–8.
72. Kumar N, AbdulRahman A, AlAli S, Otoom S, Atkin SL, AlQahtani M. Time Till Viral Clearance of Severe Acute Respiratory Syndrome Coronavirus 2 Is Similar for Asymptomatic and Non-critically Symptomatic Individuals. *Front Med.* 2021;8:2020–2.
73. Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, et al. Assessing viral shedding and infectivity of asymptomatic or mildly symptomatic patients with COVID-19 in a later phase. *J Clin Med.* 2020;9(9):1–9.

